Cancer Advances, Inc. Announces Poster Presentation at ASCO GI DURHAM, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will present a poster at the...

Cancer Advances, Inc. announces a new publication “Vaccine Against Gastrin, a Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases” in the American Journal of Physiology—Gastrointestinal and Liver Physiology Immune competent female mice with pancreatic cancer treated with Polyclonal Antibody Stimulator (PAS) vaccine had significantly smaller tumors and fewer metastases than control mice. PAS vaccine...

Cancer Advances, Inc. announces new publication: “Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Murine Pancreatic Cancer by Altering the Tumor Microenvironment”, in the journal Cancer Immunology, Immunotherapy Inactivation of the growth peptide gastrin modulates the tumor microenvironment of pancreatic cancer rendering it more susceptible to immune checkpoint antibody therapy.Polyclonal Antibody Stimulator...

Carcinoembryonic Antigen Market will expand at 6.7% CAGR to hit $3 bn by 2024: Global Market Insights, Inc. Sellbyville, Delaware, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Japan dominated the Asian carcinoembryonic antigen market and was valued around USD 74.6 million in the year 2017. Growing awareness about...

Rafael Pharmaceuticals Appoints Two Prominent Gastrointestinal Oncologists from Europe to its Medical Advisory Board to Support Global Development of CPI-613 in Pancreatic Cancer and Other Gastrointestinal Malignancies Newark, NJ, July 13, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Eric Van Cutsem...